Timing of cystectomy for superficial bladder tumors

Urologic Oncology

Volumn 5, Issue 4, 2000, Pages 162-165

  Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ALGORITHM; ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER INVASION; CYSTECTOMY; HUMAN; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

EID: 0034622423     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00061-2     Document Type: Article

References (15)

1. Herr H.W., Schwalb D.M., Zhang Z.-F.et al. Intravesical BCG therapy prevents tumor progression and death from superficial bladder cancer. Ten-year followup of a prospective randomized trial J Clin Oncol. 13:1995;1404-1407.
2. Herr H.W., Badalament R.A., Amato D.A.et al. Superficial bladder cancer treatment with BCG. A multivariate analysis of factors affecting tumor progression J Urol. 141:1989;22-29.
3. Cookson M.S., Herr H.W., Zhang Z.-F.et al. The treated natural history of high risk superficial bladder cancer. 15 year outcome J Urol. 158:1997;62-68.
4. Catalona W.J., Hudson M.A., Gillen D.P.et al. Risks and benefits of repeated courses of intravesical BCG therapy for superficial bladder cancer. J Urol. 137:1987;220-224.
5. Herr H.W. The value of a repeat TUR (reTUR) in evaluating superficial bladder tumors. J Urol. 162:1999;74-76.
6. Freeman J.A., Esrig D., Stein J.P.et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer. 76:1995;833-839.
7. Amling C.L., Thrasher J.B., Frazier H.A.et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol. 151:1994;31-35.
8. Holmang S., Hedelin H., Anderstrom C.et al. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J Urol. 153:1995;1823-1827.
9. Herr H.W. Progression of stage T1 bladder tumors after intravesical BCG. J Urol. 145:1991;40-44.
10. Klein E.A., Rogatko A., Herr H.W. Management of local BCG failures in superficial of bladder cancer. J Urol. 147:1992;601-605.
11. Herr H.W., Donat S.M. Prostatic relapse in patients with superficial bladder tumors. 15-year followup J Urol. 16:1999;1854.
12. Sarkis A.S., Dalbagni G., Cordon-Cardo C.et al. Nuclear over-expression of p53 protein in transitional cell carcinoma. A marker of disease progression J Natl Cancer Inst. 85:1993;53-59.
13. Lacombe L., Dalbagni G., Zhang Z.-F.et al. Overexpression of p53 protein in high-risk population of patients with superficial bladder cancer before and after BCG therapy. Correlation to clinical outcome J Clin Oncol. 14:1996;2646-2652.
14. Herr H.W. Tumor progression and survival in patients with T1G3 bladder tumors. 15-year outcome Br J Urol. 80:1997;762-765.
15. Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol. 16:1998;1099-1102.